Company news

IDT Australia Limited news in 2016

IDT Australia Limited's news releases, calls and decks from 2016, newest first.

View company

Completion of Initial CMAX Transaction

December 15, 2016

Mayne Pharma Announces U.S. Launch of IDTs Temozolomide

November 21, 2016

IDT: 1st generic proprietary prod shipped to US, temozolomide

November 1, 2016

IDT Divests CMAX Clinical Trial Business to Irom Group

October 27, 2016

Trading halt

October 26, 2016

Cancellation of shares

September 21, 2016

Awarded Future Industries Manufacturing Program Grant

September 6, 2016

Completion of private placement

June 29, 2016

CMAX - Opening of new Clinical Trial Facility

May 2, 2016

FDA Approval for Temozolomide

April 13, 2016

Reinstatement to Official Quotation

March 30, 2016

Manufacturing partner appointed

March 29, 2016

Thiotepa - Contract Extension and Revenues

March 8, 2016

$6m Placement to Accelerate IDTs Generic Drug Portfolio

February 11, 2016

IDT Executes US Distribution Agreement for Temozolomide

February 10, 2016

Decks in 2016